| Literature DB >> 29614994 |
Fangkun Zhao1,2,3, Bei Shi4, Ruixin Liu1,5, Wenkai Zhou1,2,3, Dong Shi1,2,3, Jinsong Zhang6,7,8.
Abstract
BACKGROUND: The distribution pattern and knowledge structure of choroidal neovascularization (CNV) was surveyed based on literatures in PubMed.Entities:
Keywords: Bibliometric analysis; Choroidal neovascularization; Co-word analysis; Social network analysis
Mesh:
Year: 2018 PMID: 29614994 PMCID: PMC5883306 DOI: 10.1186/s12886-018-0752-z
Source DB: PubMed Journal: BMC Ophthalmol ISSN: 1471-2415 Impact factor: 2.209
Fig. 1Number of publications on choroidal neovascularization from 2012 to 2016
Temporal distribution of publications on CNV in PubMed (2012-May 2017)
| Rank | Country | Publications n (%) | Top journal | Publications n (%) | Author (No. of paper) |
|---|---|---|---|---|---|
| 1 | United States | 1084 (45.8) | Retina (Philadelphia, Pa.) | 226 (9.6) | Querques G (15) |
| 2 | England | 468 (19.8) | Investigative ophthalmology & visual science | 147 (6.2) | Kim JH (15) |
| 3 | Germany | 153 (6.5) | Ophthalmology | 101 (4.3) | Parodi MB (10) |
| 4 | Switzerland | 123 (5.2) | American journal of ophthalmology | 93 (3.9) | Battaglia Parodi M (9) |
| 5 | Netherlands | 80 (3.4) | The British journal of ophthalmology | 74 (3.1) | Wang H (9) |
| 6 | New Zealand | 68 (2.9) | Graefe’s archive for clinical and experimental ophthalmology | 72 (3.0) | Iacono P (9) |
| 7 | China | 56 (2.4) | PloS one | 70 (3.0) | Tan CS (9) |
| 8 | Italy | 45 (1.9) | Eye (London, England) | 49 (2.1) | Chhablani J (8) |
| 9 | India | 40 (1.7) | Acta ophthalmologica | 48 (2.0) | Lee JH (7) |
| 10 | France | 38 (1.6) | Clinical ophthalmology (Auckland, N.Z.) | 46 (1.9) | Cheung CM (7) |
| Total | 2155 (91.1) | 926 (39.1) |
High-frequency MeSH terms from the included papers on CNV (n = 1983)
| Rank. | Major MeSH terms/ MeSH subheadings | Frequency | Proportion of frequency (%) | Cumulative percentage (%) |
|---|---|---|---|---|
| 1 | Choroidal Neovascularization / drug therapy | 498 | 6.0821 | 6.0821 |
| 2 | Angiogenesis Inhibitors / therapeutic use | 484 | 5.9111 | 11.9932 |
| 3 | Antibodies, Monoclonal, Humanized / therapeutic use | 310 | 3.7860 | 15.7792 |
| 4 | Tomography, Optical Coherence / methods | 205 | 2.5037 | 18.2829 |
| 5 | Choroidal Neovascularization / diagnosis | 204 | 2.4915 | 20.7743 |
| 6 | Choroidal Neovascularization / pathology | 192 | 2.3449 | 23.1192 |
| 7 | Wet Macular Degeneration / drug therapy | 138 | 1.6854 | 24.8046 |
| 8 | Macular Degeneration / drug therapy | 134 | 1.6365 | 26.4411 |
| 9 | Vascular Endothelial Growth Factor A / antagonists & inhibitors | 116 | 1.4167 | 27.8578 |
| 10 | Retinal Pigment Epithelium / pathology | 109 | 1.3312 | 29.1891 |
| 11 | Fluorescein Angiography / methods | 109 | 1.3312 | 30.5203 |
| 12 | Ranibizumab / therapeutic use | 91 | 1.1114 | 31.6317 |
| 13 | Choroidal Neovascularization / etiology | 91 | 1.1114 | 32.7430 |
| 14 | Photochemotherapy / methods | 90 | 1.0992 | 33.8422 |
| 15 | Recombinant Fusion Proteins / therapeutic use | 86 | 1.0503 | 34.8925 |
| 16 | Macular Degeneration / pathology | 77 | 0.9404 | 35.8329 |
| 17 | Choroidal Neovascularization / genetics | 77 | 0.9404 | 36.7733 |
| 18 | Receptors, Vascular Endothelial Growth Factor / therapeutic use | 74 | 0.9038 | 37.6771 |
| 19 | Choroid / blood supply | 69 | 0.8427 | 38.5198 |
| 20 | Visual Acuity / physiology | 65 | 0.7938 | 39.3136 |
| 21 | Choroidal Neovascularization / metabolism | 61 | 0.7450 | 40.0586 |
| 22 | Wet Macular Degeneration / diagnosis | 59 | 0.7206 | 40.7792 |
| 23 | Myopia, Degenerative / drug therapy | 55 | 0.6717 | 41.4509 |
| 24 | Macular Degeneration / diagnosis | 54 | 0.6595 | 42.1104 |
| 25 | Macular Degeneration / genetics | 49 | 0.5984 | 42.7088 |
| 26 | Polymorphism, Single Nucleotide | 47 | 0.5740 | 43.2829 |
| 27 | Polyps / drug therapy | 46 | 0.5618 | 43.8447 |
| 28 | Choroidal Neovascularization / prevention & control | 44 | 0.5374 | 44.3820 |
| 29 | Myopia, Degenerative / complications | 44 | 0.5374 | 44.9194 |
| 30 | Polyps / diagnosis | 41 | 0.5007 | 45.4201 |
| 31 | Retinal Neovascularization / drug therapy | 36 | 0.4397 | 45.8598 |
| 32 | Vascular Endothelial Growth Factor A / metabolism | 35 | 0.4275 | 46.2872 |
| 33 | Macular Degeneration / complications | 35 | 0.4275 | 46.7147 |
| 34 | Bevacizumab / therapeutic use | 35 | 0.4275 | 47.1422 |
| 35 | Choroidal Neovascularization / complications | 34 | 0.4152 | 47.5574 |
| 36 | Retinal Pigment Epithelium / metabolism | 33 | 0.4030 | 47.9604 |
| 37 | Disease Models, Animal | 32 | 0.3908 | 48.3512 |
| 38 | Macular Degeneration / metabolism | 29 | 0.3542 | 48.7054 |
| 39 | Choroidal Neovascularization / physiopathology | 26 | 0.3175 | 49.0230 |
| 40 | Angiogenesis Inhibitors / adverse effects | 24 | 0.2931 | 49.3161 |
| 41 | Wet Macular Degeneration / genetics | 23 | 0.2809 | 49.5970 |
| 42 | Antibodies, Monoclonal, Humanized / adverse effects | 23 | 0.2809 | 49.8779 |
| 43 | Retinal Drusen / diagnosis | 21 | 0.2565 | 50.1343 |
| 44 | Myopia, Degenerative / diagnosis | 20 | 0.2443 | 50.3786 |
Fig. 2Dendrogram of 44 high-frequency MeSH terms
Cluster analysis of MeSH terms
| Cluster | Number of MeSH termsa | Cluster analysis |
|---|---|---|
| 1 | 15,18, 12,27,8,20,1,2,3,7,9,23,14,34,29,31 | Clinical drug therapy of AMD, PCV and degenerative myopia |
| 2 | 35,13,28,37 | Study on etiology, complications, prevention and control of CNV in animal models |
| 3 | 40,42,10,6,16 | Pathology of CNV and adverse effect of angiogenesis inhibitor |
| 4 | 4,11,5,30,22,24,19,44,43 | Diagnostic criteria and methods of CNV, polyps, drusen and degenerative myopia. |
| 5 | 21,38,36,32 | Metabolism related researches on CNV |
| 6 | 26,41,17,25,33,39 | Genetics related researches on macular degeneration and degenerative myopia |
aRepresents the serial number of high-frequency MeSH terms
Fig. 3Strategic diagram for choroidal neovascularization
Individual centrality of CNV research from 2012-May 2017
| No. | Major MeSH terms / MeSH subheadings | Degree | Betweenness | Closeness |
|---|---|---|---|---|
| 1 | Choroidal Neovascularization / drug therapy | 1259 | 22.29 | 39.50 |
| 2 | Angiogenesis Inhibitors / therapeutic use | 1374 | 38.64 | 41.50 |
| 3 | Antibodies, Monoclonal, Humanized / therapeutic use | 818 | 28.90 | 40.00 |
| 4 | Tomography, Optical Coherence / methods | 462 | 18.61 | 38.50 |
| 5 | Choroidal Neovascularization / diagnosis | 437 | 12.57 | 37.00 |
| 6 | Choroidal Neovascularization / pathology | 331 | 41.27 | 41.50 |
| 7 | Wet Macular Degeneration / drug therapy | 404 | 13.67 | 36.50 |
| 8 | Macular Degeneration / drug therapy | 336 | 18.31 | 36.00 |
| 9 | Vascular Endothelial Growth Factor A / antagonists & inhibitors | 350 | 23.07 | 39.00 |
| 10 | Retinal Pigment Epithelium / pathology | 242 | 24.35 | 38.50 |
| 11 | Fluorescein Angiography / methods | 272 | 9.26 | 34.50 |
| 12 | Ranibizumab / therapeutic use | 307 | 8.82 | 36.00 |
| 13 | Choroidal Neovascularization / etiology | 97 | 11.03 | 36.00 |
| 14 | Photochemotherapy / methods | 219 | 4.74 | 34.50 |
| 15 | Recombinant Fusion Proteins / therapeutic use | 322 | 7.36 | 36.00 |
| 16 | Macular Degeneration / pathology | 124 | 29.47 | 38.00 |
| 17 | Choroidal Neovascularization / genetics | 96 | 8.05 | 32.50 |
| 18 | Receptors, Vascular Endothelial Growth Factor / therapeutic use | 292 | 5.88 | 35.50 |
| 19 | Choroid / blood supply | 140 | 18.72 | 38.00 |
| 20 | Visual Acuity / physiology | 186 | 6.62 | 35.50 |
| 21 | Choroidal Neovascularization / metabolism | 57 | 1.73 | 27.00 |
| 22 | Wet Macular Degeneration / diagnosis | 135 | 5.98 | 33.00 |
| 23 | Myopia, Degenerative / drug therapy | 188 | 5.38 | 33.50 |
| 24 | Macular Degeneration / diagnosis | 113 | 5.46 | 33.00 |
| 25 | Macular Degeneration / genetics | 65 | 2.26 | 30.00 |
| 26 | Polymorphism, Single Nucleotide | 87 | 3.84 | 30.50 |
| 27 | Polyps / drug therapy | 173 | 0.16 | 29.00 |
| 28 | Choroidal Neovascularization / prevention & control | 40 | 5.44 | 30.50 |
| 29 | Myopia, Degenerative / complications | 116 | 3.11 | 32.00 |
| 30 | Polyps / diagnosis | 110 | 0.59 | 26.83 |
| 31 | Retinal Neovascularization / drug therapy | 90 | 1.59 | 30.00 |
| 32 | Vascular Endothelial Growth Factor A / metabolism | 54 | 14.20 | 33.50 |
| 33 | Macular Degeneration / complications | 63 | 4.65 | 32.50 |
| 34 | Bevacizumab / therapeutic use | 123 | 2.83 | 32.50 |
| 35 | Choroidal Neovascularization / complications | 48 | 3.97 | 33.00 |
| 36 | Retinal Pigment Epithelium / metabolism | 39 | 4.63 | 29.00 |
| 37 | Disease Models, Animal | 44 | 0.92 | 28.50 |
| 38 | Macular Degeneration / metabolism | 26 | 0.79 | 24.67 |
| 39 | Choroidal Neovascularization / physiopathology | 35 | 6.35 | 30.50 |
| 40 | Angiogenesis Inhibitors / adverse effects | 48 | 0.34 | 27.50 |
| 41 | Wet Macular Degeneration / genetics | 38 | 0.12 | 25.33 |
| 42 | Antibodies, Monoclonal, Humanized / adverse effects | 62 | 2.52 | 30.00 |
| 43 | Retinal Drusen / diagnosis | 38 | 1.04 | 27.50 |
| 44 | Myopia, Degenerative / diagnosis | 44 | 1.50 | 28.00 |
Descriptive statistics for centrality measure about CNV
| Centralization | Mean ± SD | Min | Max | Network centralization |
|---|---|---|---|---|
| Degree | 225.091 ± 284.624 | 26 | 1374 | 8.791% |
| Betweenness | 9.795 ± 10.292 | 0.118 | 41.269 | 3.57% |
| Closeness | 33.235 ± 4.393 | 24.667 | 41.500 | 39.80% |
Fig. 4SNA of 44 high-frequency MeSH terms